← Back to Clinical Trials
Recruiting NCT05858437

NCT05858437 Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05858437
Status Recruiting
Phase
Sponsor Charite University, Berlin, Germany
Condition CKD (Chronic Kidney Disease) Stage 5D
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2024-01-15
Primary Completion 2025-09

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 20 Years
Study Type INTERVENTIONAL
Interventions
Sodium propionatePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2024-01-15 with a primary completion date of 2025-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.

Eligibility Criteria

Inclusion Criteria: * Body weight: \> 30kg * CKD G5 treated with hemodialysis * Continuous hemodialysis treatment for \> 3 months * Clinical stable condition * Manifestation of CKD within childhood (\<18 years) Exclusion Criteria: * Disease or dysfunctions, which disqualifies the patient * Incapacity of contract or any other circumstances, which prohibit the patient or his legal guardians from understanding setup, meaning and entity of the study * Acute infections * Immunosuppressive therapy within the last 12 weeks before the start of the study * Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study * Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study * Malignant diseases * Pregnancy * chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease * alcohol- or drug abuse * parallel participation on other interventional trials

Contact & Investigator

Central Contact

Johannes Holle, Dr. med.

✉ johannes-benjamin.holle@charite.de

📞 004930450516012

Frequently Asked Questions

Who can join the NCT05858437 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 20 Years, studying CKD (Chronic Kidney Disease) Stage 5D. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05858437 currently recruiting?

Yes, NCT05858437 is actively recruiting participants. Contact the research team at johannes-benjamin.holle@charite.de for enrollment information.

Where is the NCT05858437 trial being conducted?

This trial is being conducted at Berlin, Germany.

Who is sponsoring the NCT05858437 clinical trial?

NCT05858437 is sponsored by Charite University, Berlin, Germany. The trial plans to enroll 16 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology